$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000106282224000024 Filed on May 02, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$1.647M	$1.130M	$702.0K
YoY Change	419.56%	4608.33%	2407.14%
Cost Of Revenue	$166.0K	$31.00K	$70.00K
YoY Change	1975.0%
Gross Profit	$1.481M	$1.099M	$632.0K
YoY Change	379.29%	4479.17%
Gross Profit Margin	89.92%	97.26%	90.03%
Selling, General & Admin	$39.19M	$32.06M	$32.61M
YoY Change	30.61%	67.5%	99.69%
% of Gross Profit	2646.32%	2917.2%	5159.34%
Research & Development	$17.64M	$14.37M	$14.76M
YoY Change	21.33%	19.51%	5.62%
% of Gross Profit	1191.29%	1307.73%	2335.76%
Depreciation & Amortization	$139.0K	$144.0K	$154.0K
YoY Change	-3.47%	28.57%	49.51%
% of Gross Profit	9.39%	13.1%	24.37%
Operating Expenses	$56.84M	$46.43M	$47.37M
YoY Change	27.58%	-248.98%	56.3%
Operating Profit	-$55.35M	-$45.33M	-$46.74M
YoY Change	25.12%	45.57%
Interest Expense	-$2.211M	-$4.948M	-$3.909M
YoY Change	12.81%	-371.72%	254.4%
% of Operating Profit
Other Income/Expense, Net	$2.211M	$4.948M	$2.402M
YoY Change	70.6%	380.86%	170.8%
Pretax Income	-$53.43M	-$48.40M	-$48.24M
YoY Change	18.98%	51.55%	58.21%
Income Tax
% Of Pretax Income
Net Earnings	-$53.43M	-$48.40M	-$48.24M
YoY Change	18.98%	51.55%	58.21%
Net Earnings / Revenue	-3244.02%	-4282.92%	-6872.36%
Basic Earnings Per Share	-$0.17	-$0.20
Diluted Earnings Per Share	-$0.17	-$0.20	-$0.20
COMMON SHARES
Basic Shares Outstanding	246.2M shares	245.4M shares	244.9M shares
Diluted Shares Outstanding	310.8M shares	245.4M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$310.0M	$355.6M	$170.0M
YoY Change	20.73%	235.67%	22.89%
Cash & Equivalents	$35.62M	$96.49M	$22.47M
Short-Term Investments	$274.3M	$259.1M	$147.6M
Other Short-Term Assets	$7.675M	$7.009M	$5.130M
YoY Change	25.33%	109.35%	106.77%
Inventory	$585.0K	$514.0K	$381.0K
Prepaid Expenses
Receivables	$2.620M	$1.526M	$1.010M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$320.8M	$364.6M	$176.5M
YoY Change	21.66%	232.87%	25.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.954M	$1.843M	$7.511M
YoY Change	-11.26%	-16.49%	262.68%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$828.0K	$828.0K	$828.0K
YoY Change	-86.77%	-87.1%	-87.86%
Total Long-Term Assets	$52.51M	$52.57M	$52.88M
YoY Change	-0.93%	-1.12%	-1.03%
TOTAL ASSETS
Total Short-Term Assets	$320.8M	$364.6M	$176.5M
Total Long-Term Assets	$52.51M	$52.57M	$52.88M
Total Assets	$373.4M	$417.2M	$229.4M
YoY Change	17.88%	156.41%	18.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.22M	$8.067M	$14.39M
YoY Change	16.37%	-21.76%	38.42%
Accrued Expenses	$15.66M	$15.33M	$14.59M
YoY Change	0.31%	52.41%	14.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.88M	$23.40M	$31.55M
YoY Change	6.77%	14.86%	36.14%
LONG-TERM LIABILITIES
Long-Term Debt	$99.50M	$99.90M	$99.51M
YoY Change	0.74%	104.52%	104.84%
Other Long-Term Liabilities	$6.001M	$5.079M	$5.265M
YoY Change	9.47%	-6.88%	-2.93%
Total Long-Term Liabilities	$105.5M	$99.90M	$104.8M
YoY Change	1.2%	83.98%	1831.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.88M	$23.40M	$31.55M
Total Long-Term Liabilities	$105.5M	$99.90M	$104.8M
Total Liabilities	$133.4M	$128.4M	$136.3M
YoY Change	2.31%	71.89%	76.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.869B	-$1.815B	-$1.767B
YoY Change	12.13%	11.94%	11.14%
Common Stock	$363.0K	$248.0K	$245.0K
YoY Change	48.16%	30.53%	29.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.615M	$4.615M	$2.885M
YoY Change	59.97%	59.97%	39.98%
Treasury Stock Shares
Shareholders Equity	$240.0M	$288.9M	$93.11M
YoY Change
Total Liabilities & Shareholders Equity	$373.4M	$417.2M	$229.4M
YoY Change	17.88%	156.41%	18.08%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$53.43M	-$48.40M	-$48.24M
YoY Change	18.98%	51.55%	58.21%
Depreciation, Depletion And Amortization	$139.0K	$144.0K	$154.0K
YoY Change	-3.47%	28.57%	49.51%
Cash From Operating Activities	-$48.54M	-$55.13M	-$50.60M
YoY Change	27.34%	74.39%	134.58%
INVESTING ACTIVITIES
Capital Expenditures	$250.0K	$0.00	-$30.00K
YoY Change	79.86%	-100.0%	-102.41%
Acquisitions
YoY Change
Other Investing Activities	-$12.07M	-$110.2M	$51.93M
YoY Change	-83.79%	-993.15%	104.28%
Cash From Investing Activities	-$12.32M	-$110.2M	$51.86M
YoY Change	-83.48%	-1011.47%	114.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.642M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-14.00K	$239.4M	-40.00K
YoY Change	-100.01%	-29151.33%	-100.16%
NET CHANGE
Cash From Operating Activities	-48.54M	-$55.13M	-50.60M
Cash From Investing Activities	-12.32M	-$110.2M	51.86M
Cash From Financing Activities	-14.00K	$239.4M	-40.00K
Net Change In Cash	-60.88M	$74.03M	1.220M
YoY Change	-179.82%	-463.89%	-95.57%
FREE CASH FLOW
Cash From Operating Activities	-$48.54M	-$55.13M	-$50.60M
Capital Expenditures	$250.0K	$0.00	-$30.00K
Free Cash Flow	-$48.79M	-$55.13M	-$50.57M
YoY Change	27.54%	73.03%	121.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	23000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	247764761	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	245792668	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	248000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	245000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2108497000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1862558000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1815236000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1766839000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	31000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1528008	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	867973	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	4615000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2885000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	288867000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	93110000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	417219000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	229429000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1093000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5079000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5265000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	37000	usd
CY2023Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	24000	usd
CY2024Q1	us-gaap	Revenues Revenues	1130000	usd
CY2023Q1	us-gaap	Revenues Revenues	24000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14372000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12026000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32060000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19140000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	46463000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	31166000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-45333000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31142000	usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses	4948000	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	1821000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1884000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1029000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-48397000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31934000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	245390000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	245390000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	189014000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	189014000	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-81000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	265000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48478000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31669000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117124000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3415000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	824000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31934000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	265000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	88046000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	93110000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	241575000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	88000	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1730000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-48397000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-81000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-48397000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31934000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	144000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4302000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3415000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	517000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	265000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	226000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	516000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	234000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	133000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1879000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	867000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-166000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-400000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9108000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2770000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55130000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31613000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	183224000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	28864000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	73000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	41205000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110224000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12093000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	88000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	241425000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1730000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-400000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	239383000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-824000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74029000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20344000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22465000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46345000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96494000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26001000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	3257000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1556000	usd
CY2024Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	150000	usd
CY2023Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div>
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	84000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	216000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	58500000	usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	96494000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	259104000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	355598000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	22465000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	147561000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	170026000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	100000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	430000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	281000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	514000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	381000	usd
CY2024Q1	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3688000	usd
CY2023Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3705000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6493000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9591000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3860000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2570000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	15332000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	17157000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	99900000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5400000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5500000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	300000	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	100000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	rate
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1036000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1220000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	865000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	881000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	898000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4746000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9646000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3276000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6370000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5079000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4300000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3400000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001062822-24-000024-index-headers.html	Edgar Link	pending
0001062822-24-000024-index.html	Edgar Link	pending
0001062822-24-000024.txt	Edgar Link	pending
0001062822-24-000024-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20240331.htm	Edgar Link	pending
lxrx-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lxrx-20240331_def.xml	Edgar Link	unprocessable
lxrx-20240331_lab.xml	Edgar Link	unprocessable
lxrx-20240331_pre.xml	Edgar Link	unprocessable
lxrx-20240331_htm.xml	Edgar Link	completed
lxrx-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2024 Q2 Form 10-Q Financial Statement

#000106282224000024 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2024 Q2 Form 10-Q Financial Statement

#000106282224000024 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx